Announced details
Regenerative medicine and regenerative medicine-related services for medical institutions
The Company has entered into an exclusive license agreement with 株式会社Meis Technology and 株式会社バイオラボ concerning a method for producing a liquid containing high concentrations of exosome components. The Company will supply related equipment, disposable products, related materials and other items to the affiliated medical institutions.
The locations, representatives, business activities, capital, and year of establishment of 株式会社Meis Technology and 株式会社バイオラボ are Not disclosed. Information on the affiliated medical institutions is also Not disclosed.
The impact on consolidated results for the fiscal year ending March 2027 is currently under review. At this time, the Company has determined that there are no matters requiring a revision to its full-year consolidated earnings forecast.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | NeoCella (Neocella) |
| Counterparty | 株式会社Meis Technology, 株式会社バイオラボ, and affiliated medical institutions (names not disclosed) |
| Counterparty overview | The locations, representatives, business activities, capital, and year of establishment of 株式会社Meis Technology and 株式会社バイオラボ are Not disclosed. Information on the affiliated medical institutions is also Not disclosed. |
| Relationship with the Company | The Company has entered into an exclusive license agreement with 株式会社Meis Technology and 株式会社バイオラボ concerning a method for producing a liquid containing high concentrations of exosome components. The Company will supply related equipment, disposable products, related materials and other items to the affiliated medical institutions. |
| Contract Date | The execution of the exclusive license agreement was disclosed in a filing dated 30 September 2025 (the agreement date itself is Not disclosed) |
| Launch date | July 2026 (scheduled) |
| Applicable area | Regenerative medicine and regenerative medicine-related services for medical institutions |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review. At this time, the Company has determined that there are no matters requiring a revision to its full-year consolidated earnings forecast. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to promote technological innovation and wider adoption in the regenerative medicine field, as well as to expand the adoption of regenerative medicine-related services through affiliated medical institutions.